Importantly, in a phase II clinical trial, a humanized anti-EGFR antibody panitumumab in combination with neoadjuvant chemotherapy led to remarkably high pathological complete response rate in patients with triple-negative IBC38, indicating that EGFR is a promising therapeutic target in IBC. Here, EGFR is linked to inflammatory breast carcinoma.